文献速递皮肤肿瘤

可切除III/IV期黑色素瘤新辅助免疫检查点抑制剂的法国全国真实世界研究(NEOMEL)

Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: a nationwide real-life study in France (NEOMEL).
PubMed 文献 · Br J Dermatol · 2026-01-01

NEOMEL为法国回顾性多中心队列研究,纳入2016年7月至2024年4月接受新辅助免疫检查点抑制剂(NT-ICI)治疗的可切除III/IV期黑色素瘤患者174例,其中149例(86%)接受手术。NT-ICI的病理完全缓解(pCR)率为43%(95%CI 34.9-51.3),抗PD-1单药与IPI-NIVO联合的pCR率分别为44.7%与37.1%(P=0.427)。联合治疗严重免疫相关不良事件(irAEs)发生率高于单药(24.4% vs 3.1%,P<0.001)。

要点

  • NT-ICI在真实世界中pCR率达43%,支持其用于可切除III/IV期黑色素瘤。
  • IPI-NIVO联合治疗严重irAEs发生率24.4%,显著高于抗PD-1单药的3.1%。
  • 达到pCR者无复发生存(RFS)显著优于未达pCR者(HR 0.218,P=0.0009)。

核心结论

  • 真实世界研究证实NT-ICI对可切除转移性黑色素瘤有效,病理缓解率高。
  • IPI-NIVO双免疫联合治疗与严重irAEs风险升高相关。

研究设计与样本

  • 法国回顾性多中心队列研究(NEOMEL),由法国皮肤肿瘤协作组(Groupe de Cancérologie Cutanée)皮肤肿瘤科医生纳入患者。
  • 纳入2016年7月至2024年4月接受NT-ICI治疗的可切除III或IV期黑色素瘤(AJCC第8版)患者174例,其中149例(86%)接受手术。
  • 治疗方案为NT抗PD-1单药或抗CTLA-4联合抗PD-1(1 mg/kg IPI+3 mg/kg NIVO或3 mg/kg IPI+1 mg/kg NIVO)。
  • 主要终点为pCR率;次要终点包括按国际新辅助黑色素瘤联盟标准的病理缓解、影像学缓解、irAEs(含≥3级)及RFS和EFS。

主要发现

  • 174例中149例(86%)接受手术,NT-ICI的pCR率为43%(95%CI 34.9-51.3)。
  • 抗PD-1单药pCR率44.7%(95%CI 35.4-54.3),IPI-NIVO联合37.1%(95%CI 21.5-55.1),P=0.427。
  • 主要病理缓解(完全+近完全)率为53.2%;影像学缓解率50%,含12例影像学完全缓解,其中11例同时为pCR。
  • 严重irAEs在IPI-NIVO联合组发生率为24.4%,抗PD-1单药组为3.1%(P<0.001)。
  • 中位RFS为29.61个月(95%CI 27.70-未达到),pCR者RFS显著优于非pCR者(HR 0.218,95%CI 0.082-0.583;P=0.0009);中位EFS为35.8个月(95%CI 29-未达到)。

关键数值与推荐

  • pCR定义为病理完全缓解,NT-ICI总体pCR率43%(95%CI 34.9-51.3)。
  • 主要病理缓解(完全+近完全)率为53.2%。
  • 严重irAEs定义含≥3级免疫相关不良事件,IPI-NIVO组24.4% vs 抗PD-1组3.1%(P<0.001)。

临床怎么用

  • 可切除III/IV期黑色素瘤患者可考虑NT-ICI以争取高病理缓解率。
  • 选择IPI-NIVO联合方案时需权衡严重irAEs风险显著高于抗PD-1单药。
  • pCR与更优RFS相关,提示病理缓解可作为预后参考指标。

局限性

  • 回顾性研究设计,存在选择偏倚和信息偏倚可能。
  • 真实世界数据,NT-ICI方案及评估时间可能存在异质性。
  • 作者指出结果需进一步研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the clear therapeutic benefits of neoadjuvant treatment (NT) with immune checkpoint inhibitors (ICIs) in clinical trials, the efficacy of NT with ICIs (NT-ICI) and the optimal regimen for patients with resectable metastatic melanoma (RMM) remain to be confirmed in real life. OBJECTIVES: To assess the efficacy and safety of NT-ICI among patients with RMM in real life. METHODS: NEOMEL is a French retrospective multicentric cohort study. Dermato-oncologists from the French Groupe de Cancérologie Cutanée (Cutaneous Cancer Group) included patients treated with NT-ICI for RMM (stage III or IV, American Joint Committee on Cancer 8th edn) between July 2016 and April 2024. Patients were treated either with NT anti-programmed cell death protein-1 (anti-PD-1) monotherapy or with the combination of anticytotoxic T-lymphocyte-associated protein-4 (anti-CTLA-4) plus anti-PD-1 [1 mg kg-1 ipilimumab (IPI) and 3 mg kg-1 nivolumab (NIVO) or 3 mg kg-1 IPI and 1 mg kg-1 NIVO]. The primary endpoint was the pathological complete response (pCR) rate. The secondary endpoints were pathological response according to the International Neoadjuvant Melanoma Consortium criteria, radiological response, the occurrence of immune-related adverse events (irAEs) including those of ≥ grade 3 and outcomes with recurrence-free survival (RFS) and event-free survival (EFS). RESULTS: Among the 174 included patients, 149 (86%) underwent surgery. NT-ICI achieved a high pCR rate of 43% [95% confidence interval (CI) 34.9-51.3], including 44.7% (95% CI 35.4-54.3) with NT-anti-PD-1 and 37.1% (95% CI 21.5-55.1) with NT-IPI-NIVO (P = 0.427). The major (complete + near complete) pathological response rate was 53.2%. Radiological responses were observed in 50% of patients, including 12 radiological complete responses, of whom 11 were also pCRs. Severe irAEs occurred more frequently with NT-IPI-NIVO (24.4%) compared with NT-anti-PD-1 (3.1%) (P < 0.001). The median RFS was 29.61 months [95% CI 27.70-not reached (NR)] with significantly higher RFS in patients with pCR than no pCR [hazard ratio 0.218 (95% CI 0.082-0.583); P = 0.0009]. The median EFS was 35.8 months (95% CI 29-NR). CONCLUSIONS: In this retrospective real-life study, the efficacy of NT-ICI is confirmed in patients with RMM, achieving high pathological response rates. However, dual checkpoint inhibition with IPI-NIVO was associated with a higher risk of severe irAEs. These findings underscore the relevance of NT-ICI for RMM in clinical practice and require further confirmation. Metastatic melanoma (MM) is an advanced skin cancer that has spread to other parts of the body. In cases where surgery is possible, treatment before surgery (called neoadjuvant treatment) is being explored. Immune checkpoint inhibitors (ICIs) are being explored to improve outcomes. They have a mortality rate at 10 years varying from 20% to 80%. There have been two previous clinical trials. They showed that pre-surgery (neoadjuvant) treatment with ICIs is more effective than post-surgery treatment. Evidence from real-life practice is still limited. This study was done in France. We looked at the real-world effectiveness and safety of ICIs in treating operable MM. We wanted to find out two things. How effective are these pre-surgery treatments in reducing cancer before surgery? Are they safe for patients with MM? We looked at two types of ICI treatments. One uses a single drug (anti-PD-1). Another combines two drugs (anti-CTLA-4 plus anti-PD-1). We measured several parameters. How many patients had no cancer left in their tissue after treatment (pathological complete response, or pCR)? How often did the cancer come back? Were there any treatment-related side effects? We studied 174 patients with MM treated between 2016 and 2024, of whom 149 underwent surgery. pCR was achieved in 43% of patients. This means that the tumour had completely disappeared in 43% of patients with the pre-surgery treatment. The pre-surgery treatment with anti-PD-1 was less likely to cause severe immune-related side effects (3.1%). In comparison, the combination therapy (anti-PD-1 plus anti-CTLA-4) had a side effect rate of 24.4%. Furthermore, patients who achieved pCR were less likely to have their cancer recur. These findings show that pre-surgery ICIs (neoadjuvant treatment) are effective for operable MM. They can lead to significant cancer reduction before surgery in real life. However, the combination therapy comes with a higher risk of serious side effects. This information could help doctors and patients make more informed treatment decisions. More studies are needed to confirm these results.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Nardin C, Cavalieri C, Lebbé C, et al. Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: a nationwide real-life study in France (NEOMEL). Br J Dermatol. 2026. PMID: 40658732. doi:10.1093/bjd/ljaf268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。